Radiation Therapy Overcomes Primary Resistance to Pembrolizumab in Immunologically Cold NSCLC
Key Insights
A phase II clinical trial demonstrated that stereotactic body radiation therapy combined with pembrolizumab significantly improved progression-free survival in patients with immunologically "cold" non-small cell lung cancers that typically resist immunotherapy.
Patients with low tumor mutation burden, no PD-L1 (search) expression, and Wnt pathway (search) mutations showed enhanced immune responses including interferon-γ (search) activation and expanding T-cell clones after receiving radiation therapy.
The study captured the abscopal effect at distant tumor sites, linking systemic immune responses with clinical outcomes in tumors previously unlikely to respond to immunotherapy alone.
A groundbreaking phase II clinical trial has demonstrated that stereotactic body radiation therapy can overcome primary resistance to pembrolizumab in patients with immunologically "cold" non-small cell lung cancer (NSCLC), offering new hope for patients whose tumors typically do not respond to immunotherapy alone. The research, published in Nature Cancer, provides compelling evidence that radiation therapy can transform the immune landscape of resistant tumors.
Targeting Immunologically Cold Tumors
The study focused on a particularly challenging subset of NSCLC patients whose tumors are characterized by low tumor mutation burden, absent PD-L1 (search) expression, and Wnt pathway (search) mutations. These immunologically "cold" tumors represent a significant unmet medical need, as they typically show poor responses to checkpoint inhibitor therapy.
"For a fraction of lung cancers where we aren't expecting therapy responses, radiation may be particularly effective to help circumvent primary resistance to immunotherapy; this could potentially be applicable to acquired resistance, too," stated senior study author Valsamo Anagnostou, MD, PhD, Co-Director of the Upper Aerodigestive Malignancies Program at Johns Hopkins Kimmel Cancer Center (search).
Comprehensive Multiomic Analysis
Researchers conducted multiomic analyses of 293 serial tissue and blood samples from 72 patients with metastatic NSCLC, comparing stereotactic body radiation therapy followed by pembrolizumab versus immunotherapy alone. The samples were collected before treatment and after 3 to 6 weeks of treatment, allowing researchers to track the immunostimulatory effects of radiation therapy at both cellular and molecular levels.
The study design enabled investigators to examine the abscopal effect of radiation therapy, where localized radiation treatment triggers systemic immune responses that can affect distant tumor sites.
Significant Clinical and Molecular Outcomes
Patients with immunologically cold tumors who received the combination treatment achieved significantly longer progression-free survival compared to those receiving pembrolizumab alone. The molecular analysis revealed profound changes in the immune microenvironment following radiation therapy.
These patients demonstrated activation of interferon-γ (search), interferon-α (search), and antigen processing pathways, along with enriched presentation gene sets in nonirradiated tumor sites after receiving stereotactic body radiation therapy. The treatment also led to expanding new and preexisting T-cell clones in both tumor and blood compartments, as well as clonal neoantigen-reactive autologous T-cell responses.
"It was super exciting.... We not only captured the abscopal effect, but we linked the immune response with clinical outcomes in tumors where one would not expect to see immunotherapy responses," said Dr. Anagnostou.
Systemic Immune Activation
The research revealed that radiation therapy can bolster systemic antitumor immune responses even in lung cancers unlikely to respond to immunotherapy alone. Lead study author Justin Huang, Undergraduate Research Assistant at Johns Hopkins University, emphasized the clinical significance of these findings.
"Our findings highlight how radiation can bolster the systemic antitumor immune response in lung cancers unlikely to respond to immunotherapy alone," stated Huang, who led the multiomic analyses. "Our work underscores the value of international, interdisciplinary collaboration in translating cancer biology insights to clinical relevance."
Future Research Directions
Building on these promising results, the study authors are developing methods to track the immune system's response to immunotherapy using liquid circulating tumor DNA testing. This approach could provide real-time monitoring of treatment response and help identify patients most likely to benefit from combination therapy.
The findings were also presented at the 2025 American Association for Cancer Research Annual Meeting, highlighting the potential for this treatment approach to reach patients whose cancers don't currently respond to standard immunotherapy protocols.